RxDoctor Payments Data

Matthew Uhlman, MD

Urology · Yakima, WANPI 1144546433

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (40.3%), gifts and education — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Butterfly Network, Inc. at 33.4% of the total. Reporting peaked in 2019 at $7,529 and has fallen 92.6% since, to $558 in 2025. Among urology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,216in general payments, 2019–2025

Across 233 payments — averaging $56.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Butterfly Network, Inc.$4K
  • Intuitive Surgical$3K
  • Astellas Pharma US Inc$1K
  • Procept Biorobotics Corporation$1K
  • Johnson & Johnson$516
  • Pfizer$462
  • plus $3K from 41 others

What the payments were for

  • Travel & lodging$1,65913%
  • Food & beverage$5,32440%
  • Education$1,81514%
  • Gifts$4,41833%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,216 in reported general payments places this provider in the 90th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$265,512
Medicare patients
774
Services billed
36,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron89$66,060
GemtesaVibegron46$28,982
Tamsulosin Hcl382$5,841
Finasteride424$5,219
Methenamine Hippurate82$4,118
Potassium Citrate ErPotassium Citrate56$3,923
Tolterodine Tartrate ErTolterodine Tartrate18$3,631
Solifenacin Succinate111$3,539
Desmopressin Acetate14$3,136
Estradiol24$2,172
Oxybutynin Chloride ErOxybutynin Chloride109$1,780
Cephalexin186$1,695
Dutasteride42$1,624
Trospium Chloride15$920
NitrofurantoinNitrofurantoin Macrocrystal20$696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,258$66,06089 claims
Sumitomo Pharma America, Inc.Gemtesa$83$28,98246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 274 urology providers in Washington.

Other urology in Yakima

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →